pdufa.bio

Cannabidiol oral

Page updated ·next FDA decision on the calendar ·Data as of Nov 5, 2026 5:03 AM ET

Cannabidiol oral is a Jazz Pharmaceuticals plc program in oral cannabidiol capsule formulation. Its PDUFA date is Apr 16, 2027, the FDA's goal date to complete review of the application. Every date links its source.

JAZZ catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Oral cannabidiol capsule formulation. Sponsor: Jazz Pharmaceuticals plc (JAZZ). Market-cap tier at the time we tracked it: Large. We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

PDUFA · Apr 16, 2027JAZZ

Specialist biotech funds holding JAZZ, 13F for the quarter ended June 30, 2026

FundSharesValue at quarter endFiling
Perceptive Advisors170,000$41.0 millionfiled August 14, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is Cannabidiol oral's next FDA decision or readout?

Cannabidiol oral's PDUFA date is Apr 16, 2027. That is the FDA's goal date to complete review of the application; the agency can act earlier or extend it.

What happened at Cannabidiol oral's most recent FDA decision?

No FDA decision for Cannabidiol oral is in our archive yet.

What is Cannabidiol oral used for?

In our records Cannabidiol oral is under review or in development for Oral cannabidiol capsule formulation.

Who makes Cannabidiol oral?

Jazz Pharmaceuticals plc (JAZZ).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.